This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Type 2 Diabetes Mellitus
and you are
between 18 and 65
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

This study will evaluate the absolute oral bioavailability (F) and fraction absorbed (Fa) of ertugliflozin following oral administration of unlabeled ertugliflozin (MK-8835) and intravenous (IV) and oral administration of 14^C-labeled ertugliflozin in healthy male participants.

Provided treatments

  • Drug: Unlabeled ertugliflozin for oral use
  • Drug: 14^C-labeled ertugliflozin for IV use
  • Drug: 14^C-labeled ertugliflozin for oral use
Tris trial is registered with FDA with number: NCT02411929. The sponsor of the trial is Merck Sharp & Dohme Corp. and it is looking for 8 volunteers for the current phase.
Official trial title:
A Phase 1, Open-Label, Non-Randomized, 2-Period, Fixed Sequence, Study to Assess the Absolute Bioavailability and Fraction Absorbed of Ertugliflozin in Health Male Subjects Using a 14^C-Microdose Approach